Tecaginlimab  (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)

Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Bispecific; Humanized

Tecaginlimab binds to recombinant human CD40 and 4-1BB with affinities of 1.0 nM and 0.17 nM, respectively^[1].
Tecaginlimab (0.001-1 µg/mL; 5 d) induces dendritic cell (DC) maturation in vitro^[1].
Tecaginlimab (0.2 µg/mL; 10-15 d) enhances T-cell activation in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tecaginlimab (0.0008-0.2 µg/mL; 4 d) enhances tumor-infiltrating lymphocyte expansion ex vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2253891-70-0

Liquid

Colorless to light yellow

[Tecaginlimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Tecaginlimab on AHC2 biosensor, can bind 4-1BB/TNFRSF9 Protein, Human (HEK293, His, HY-P70678) with an affinity constant of 5.270E-11 M as determined in BLI assay.

• [1]. Muik A, et, al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022 Jun;10(6):e004322.  [Content Brief]